Innography Releases Three High-Value Professional Service Offerings

AUSTIN, Texas, Jul 09, 2014 (BUSINESS WIRE) --Innography , the innovative software provider of better intellectual property answers for improved business results, today announces three brand new consulting service offerings powered by the firm’s industry-leading IP analytics platform, Innography Advanced Analysis . The innovative professional services include the IP Due Diligence Report, the License Candidate Identification analysis and the IP Maturity Model Assessment.

“Innography’s latest three packaged service offerings give patent owners unique insights into their intellectual property portfolios and opportunities,” said John F. Martin, chief executive officer and chairman of Innography. “By leveraging our best-of-breed corrected patent data and proprietary analytics, these services help clients quickly determine possibilities and risks when making important patent-related decisions.”

http://www.marketwatch.com/story/innography-releases-three-high-value-professional-service-offerings-2014-07-09

India: Patent Counter Claim And Revocation Petition Cannot Be Pursued Simultaneously: SC

• The Supreme Court in this decision has indicated its desire to avoid multiplicity of proceedings on the same issue before different forums.
• Post grant opposition of a patent initiated by any person interested, will abate the right of the same person to file a revocation petition or a counter claim of revocation of the same patent.
• The revocation petition of patent and counter claim of revocation of patent in an infringement suit cannot be availed as simultaneous remedy.

http://www.mondaq.com/india/x/324912/Patent/PATENT+COUNTER+CLAIM+AND+REVOCATION+PETITION+CANNOT+BE+PURSUED+SIMULTANEOUSLY+SC

NY firm sues Aurobindo for Alzheimer’s generic drug

New York-based Forest Laboratories has sued Indian generics firm Aurobindo Pharma for intending to make a similar version of patented drug Namenda, used to treat Alzheimer’s.

The case filed on June 27 alleges infringement of patent No. 5,061,703 titled 'Adamantane derivatives in the prevention and treatment of cerebral ischemia' which was granted by the US patent and trademark office in June 2007. While Frankfurt-based Merz pharma is the owner of the patent, the exclusive licensee is Forest Laboratories.

Aurobindo had subm­itted an abbreviated new dr­ug application (ANDA) to FDA seeking approval to make and market a generic version of the drug around mid-May. The 703 patent expires in April 2015.

Forest Laboratories has sought Delaware district court’s intervention to prevent Aurobindo selling this drug before the expiry of the patent, including exclusivities and extensions. It also wants monetary relief from the Indian company. Reports suggest that in the last quarter of 2013, Namenda had sales of $379.2 million, while Namenda XR logged $37.8 million.

The Forest website says the company plans to discontinue the sale of Namenda 5 mg and 10 mg tablets in fall 2014. “This action is not due to any safety or efficacy issue related to Namenda tablets. The oral solution of Namenda will continue to be available, along with Namenda XR (memantine HCl) extended-release capsules. This drug is for the treatment of moderate to severe dementia of the Alzheimer’s type. Namenda, a twice daily immediate release formulation, was approved in October 2003."

Source and Full News:
http://www.mydigitalfc.com/news/ny-firm-sues-aurobindo-alzheimer%E2%80%99s-generic-drug-008

Will India Be the Uber of the Pharmaceutical Industry?

http://truth-out.org/opinion/item/24670-will-india-be-the-uber-of-the-pharmaceutical-industry

Many self-styled libertarians have been celebrating the rise of Uber. Their story is that Uber is a dynamic start-up that has managed to disrupt the moribund cab industry. The company now has a market capitalization of $17 billion.

While Uber's market value probably depends mostly on its ability to evade the regulations that are imposed on its competitors, the company has succeeded in transforming the industry. At the least we are likely to see a modernized regulatory structure that doesn't saddle cabs with needless regulations and fees.

Unfortunately, the taxi industry is not the only sector of the U.S. economy that can use modernization. The pharmaceutical industry makes the taxi industry look like cutting edge social media. The government imposed barriers to entry in the pharmaceutical industry don't just raise prices by 20 or 30 percent, as may be the case with taxi fares, they raise prices by a factor or ten, twenty, or even one hundred (that would be 10,000 percent).

Pluristem Receives Patent in India for Cell Therapy Production Methods and Compositions

Pluristem Therapeutics Inc . PSTI -1.23% (tase:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted Patent No. 261087 from India's Office of the Controller General of Patents, Designs & Trade Marks for a patent titled, "Methods for Cell Expansion and Conditioned Media Produced Thereby for Therapy."

The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company's key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells. It also covers the composition of cells derived using this method.

"We believe Pluristem is the global leader in the commercial-scale production of placenta-derived cells. In our manufacturing facility, we use proprietary 3-dimensional cell expansion technology that gives us the ability to precisely control cell growth based on the intended indication to be treated. Our ability to do this on a large scale is one of our key assets," stated Pluristem CEO Zami Aberman.

http://www.marketwatch.com/story/pluristem-receives-patent-in-india-for-cell-therapy-production-methods-and-compositions-2014-06-16?reflink=MW_news_stmp

RECENT TRADEMARK DISPUTES: PEPSICO

Delhi High Court recently decided a Trademark case involving the soft drink giant, Pepsico India Holdings Pvt. Ltd. (Plaintiff) involving the Trademark ‘Aquafina’ used for its bottled water products. Justice G S Sistani restrained the usage of the deceptively similar trademark ‘Aquafine’ by Aqua Mineral (India) (Defendant).

The Hon’ble court acknowledged the successful efforts of Pepsico India in establishing the trademark, trade name logo and label ‘Aquafina’ being used in respect of their product and said that the label was created for and on behalf of the Plaintiff, adding that it was an original artistic work falling within the meaning of Section 2 (c) of the Copyright Act, 1957. The court further held that the usage of a mark that was identical and/or deceptively similar to the Plaintiff’s trademark by the Defendant, in respect of packaged drinking water, was a clear cut infringement of Copyright and Trademark rights enjoyed by the Plaintiff.

India: A Glimpse Of Recent Developments In Patent Arena

The US Trade Representative 301 Report found that Indian IP regime favors the native and therefore, the chances of US downgrading India in this report was most likely.1 However, the Indian government refused to participate in US unilateral investigation while defending its IP regime. Essentially, India is compliant with its commitments under TRIPS and has used flexibilities which are available to WTO members and that is entirely within the limit and commitments made by India under TRIPS and WTO agreements. India is also gradually aligning its IP regime to the global regime. In the domain of patents, India became a contracting state to the Patent Cooperation Treaty ("PCT") on December 7, 1998 and this heralded an era of regulatory and procedural changes. Now, the Indian Patent Office ("IPO") enjoys the privileges enjoyed by the patent offices of other developed nations. The recent unprecedented decision of granting compulsory license for manufacturing patented drugs by Indian patent authorities have also evoked mixed responses and, turned the attention of other countries to the patent law developments in India.

The present bulletin will discuss the various changes carried out to the IPO by WIPO followed by the streamlining of the procedural aspects of patent registrations in view of the newly acquired status by IPO and, also, the concept and recent grant of compulsory license.

Full News:
http://www.mondaq.com/india/x/319732/Patent/A+Glimpse+Of+Recent+Developments+In+Patent+Arena